Bristol-Myers Squibb Co  

(Public, NYSE:BMY)   Watch this stock  
Find more results for BMY
+0.68 (1.14%)
Feb 12 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 59.16 - 60.41
52 week 51.82 - 70.87
Open 60.20
Vol / Avg. 5.98M/8.37M
Mkt cap 101.58B
P/E 64.56
Div/yield 0.38/2.52
EPS 0.93
Shares 1.66B
Beta 0.55
Inst. own 75%
May 4, 2016
Bristol-Myers Squibb Co Annual Shareholders Meeting (Estimated) - 10:00AM EDT - Add to calendar
Apr 26, 2016
Q1 2016 Bristol-Myers Squibb Co Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Feb 10, 2016
Bristol-Myers Squibb Co at Leerink Partners Global Healthcare Conference
Jan 28, 2016
Q4 2015 Bristol-Myers Squibb Co Earnings Call
Jan 28, 2016
Q4 2015 Bristol-Myers Squibb Co Earnings Release
Jan 12, 2016
Bristol-Myers Squibb Co at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -4.39% 9.85%
Operating margin -8.02% 7.61%
EBITD margin - 15.30%
Return on average assets -2.37% 4.98%
Return on average equity -5.39% 10.75%
Employees 25,000 -
CDP Score - 98 B


NEW YORK, NY 10154
United States - Map
+1-212-5464000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Company's products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company manufactures its products in the United States, Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers, such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print, radio, television, and digital advertising and promotion. In addition, the Company holds rights to F001287, which is a preclinical, small-molecule IDO1-inhibitor.

Officers and directors

Giovanni Caforio M.D. Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Charles A. Bancroft Chief Financial Officer, Executive Vice President
Age: 55
Bio & Compensation  - Reuters
Louis S Schmukler President - Global Manufacturing and Supply
Age: 59
Bio & Compensation  - Reuters
Francis M. Cuss Executive Vice President, Chief Scientific Officer
Age: 60
Bio & Compensation  - Reuters
Sandra Leung Executive Vice President, General Counsel and Corporate Secretary
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Paul von Autenried Senior Vice President - Enterprise Services, Chief Information Officer
Age: 53
Bio & Compensation  - Reuters
Anne Nielsen Senior Vice President, Chief Compliance and Ethics Officer
Age: 54
Bio & Compensation  - Reuters
Joseph C. Caldarella Senior Vice President, Corporate Controller
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ann Powell Judge Senior Vice President - Global Human Resources
Age: 49
Bio & Compensation  - Reuters
John E. Elicker Senior Vice President - Public Affairs
Age: 55
Bio & Compensation  - Reuters